Systemic administration of RAR-α-selective retinoids have been shown to inhibit Th1-associated immune responses such as delayed type hypersensitivity (DTH) [21,29], the progression of experimental arthritis [23] and skin allograft rejection [30]. This evidence concerns the gene RARA and Arthritis.